Geron Corporation (LON:0IV3)

Market Cap	1.23B
Revenue (ttm)	22.00M
Net Income (ttm)	-150.11M
Shares Out	n/a
EPS (ttm)	-0.24
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	29,702
Average Volume	8,206
Open	2.640
Previous Close	2.629
Day's Range	2.570 - 2.640
52-Week Range	1.731 - 3.700
Beta	0.52
RSI	33.50
Earnings Date	Feb 26, 2025

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquarte...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1990
• Employees: 141
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0IV3

Financial Performance

In 2023, Geron's revenue was $237,000, a decrease of -60.23% compared to the previous year's $596,000. Losses were -$184.13 million, 29.8% more than in 2022.

Financial numbers in USD